

Frozen Components and Platelets Katy Cowan, PBM Practitioner, NHSBT



"Club '96"

January 1996

UK food chain deemed "safe" from vCJD



Risk Reduction by NHSBT

- Exclusion of "at risk" donors
 - including all donors to have received a blood transfusion or solid organ transplant since 1980.
- Leucodepletion
- Importing plasma derivatives
 - from countries with low risk of vCJD
- Providing imported, virus inactivated FFP for "Club '96"



Plasma and NHSBT

- 2002 MBFFP from UK donors for children born on or after 1.1.96
- 2005 MBFFP produced from US sourced plasma as a risk reduction measure
 - MBFFP extended to all patients under 16
- 2012 Decision to continue providing MBFFP for all recipients born after 1.1.96 even after they reached 16



Solvent Detergent treated plasma

- Alternative to MBFFP
- Not produced by NHSBT
- Inactivates all lipid enveloped viruses
- Pros and cons for both
 - Availability
 - Price
 - Supply



Advisory Committee on the Safety of Blood, Tissues and Organs SaBTO

 Provides independent advice to the UK government and the devolved administrations on the most appropriate way to ensure the safety of blood, cells, tissues and organs for transfusion or transplantation.



- 2007 DoH requests...
 - at least 80% platelets come form single donors to minimise the risk of vCJD
- 2008 (Jan) SABTO inaugural meeting
- 2008 (July) SABTO recommendations
 - 'the UK blood service should move as far as possible towards 100% apheresis platelets, but that as a minimum, 80% of platelets should be collected by apheresis "to minimise risk of transmission of vCJD"



- 2013 (Sept) SABTO
 - reconsidered recommendation following better understanding of risk of whole blood vCJD infectivity and the prevalence of vCJD
 - 80% minimum provision of apheresis platelets no longer necessary
 - Both pooled and apheresis platelets should be resuspended in Platelet Additive Solution (PAS)
 - Each UK blood service should set their own level of apheresis to collect.
- DoH has accepted this recommendation



- NHSBT
 - Moving from 80% to 60% apheresis platelets by April 2016 with further review at that point.



Indications for Apheresis

- Neonates
- Paediatrics (where available) Never been recommended but recognised as best practice.
- Patients requiring HLA and HPA selected components due to presence of HLA / HPA antibodies or in cases of NAIT
- Patients requiring IgA deficient components due to being IgA deficient and having had a previous reaction.



"Club '96"

- "Special" group of patients
- Potential "clean" donor pool
- Previously contained
- Now need to be far more alert